Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19 ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half–Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study Read more »